Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

822 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 822 results

Not applicableWithdrawnNCT07195617
What this trial is testing

Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Testing effectiveness (Phase 2)Study completedNCT00002652
What this trial is testing

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
University of Arkansas
Testing effectiveness (Phase 2)Study completedNCT03439293
What this trial is testing

Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Takeda 61
Testing effectiveness (Phase 2)Study completedNCT00866138
What this trial is testing

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Who this might be right for
Multiple Myeloma
AB Science 24
Early research (Phase 1)Ended earlyNCT06163898
What this trial is testing

Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 4
Not applicableLooking for participantsNCT05160584
What this trial is testing

Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium 300
Early research (Phase 1)Looking for participantsNCT04910568
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 186
Early research (Phase 1)UnknownNCT04727008
What this trial is testing

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sichuan University 12
Not applicableNo Longer AvailableNCT05503550
What this trial is testing

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Early research (Phase 1)UnknownNCT05007418
What this trial is testing

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sorrento Therapeutics, Inc. 54
Testing effectiveness (Phase 2)UnknownNCT01002703
What this trial is testing

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Leipzig 50
Early research (Phase 1)Ended earlyNCT04123418
What this trial is testing

WVT078 in Patients With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma (MM)
Novartis Pharmaceuticals 56
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Testing effectiveness (Phase 2)Study completedNCT00044018
What this trial is testing

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 102
Early research (Phase 1)UnknownNCT04295018
What this trial is testing

BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Testing effectiveness (Phase 2)Ended earlyNCT01646762
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Mayo Clinic 13
Large-scale testing (Phase 3)Active Not RecruitingNCT04181827
What this trial is testing

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 419
Testing effectiveness (Phase 2)Study completedNCT01001442
What this trial is testing

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Biotest Pharmaceuticals Corporation 35
Early research (Phase 1)Looking for participantsNCT06375044
What this trial is testing

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd. 130
Next Page